Skip to main content
. 2022 Feb 12;11(4):e024159. doi: 10.1161/JAHA.121.024159

Figure 2. Major atherothrombotic events with clinical implementation of CYP2C19‐guided antiplatelet therapy after PCI.

Figure 2

A, All patients. B, Patients with an ACS indication for PCI. C, Patients with a non‐ACS/elective indication for PCI. ACS indicates acute coronary syndrome; LOF, loss‐of‐function; and PCI, percutaneous coronary intervention. Weighted data are shown for patients with a CYP2C19 loss‐of‐function (LOF) allele treated with clopidogrel (LOF‐clopidogrel) or alternative therapy (LOF‐alternative) and for patients without a LOF allele treated with clopidogrel (non‐LOF‐clopidogrel) or alternative therapy (non‐LOF‐alternative). Note that patients were standardized to 2 different populations based on LOF allele status.